Viking Therapeutics (VKTX) Liabilities and Shareholders Equity: 2014-2025
Historic Liabilities and Shareholders Equity for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $739.4 million.
- Viking Therapeutics' Liabilities and Shareholders Equity fell 21.16% to $739.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year increase of 3.78%. This contributed to the annual value of $908.3 million for FY2024, which is 146.50% up from last year.
- Viking Therapeutics' Liabilities and Shareholders Equity amounted to $739.4 million in Q3 2025, which was down 10.68% from $827.9 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Liabilities and Shareholders Equity ranged from a high of $967.5 million in Q1 2024 and a low of $150.9 million during Q1 2023.
- For the 3-year period, Viking Therapeutics' Liabilities and Shareholders Equity averaged around $681.6 million, with its median value being $827.9 million (2025).
- In the last 5 years, Viking Therapeutics' Liabilities and Shareholders Equity fell by 25.75% in 2022 and then spiked by 541.19% in 2024.
- Viking Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $210.7 million in 2021, then dropped by 20.00% to $168.5 million in 2022, then surged by 118.65% to $368.5 million in 2023, then surged by 146.50% to $908.3 million in 2024, then decreased by 21.16% to $739.4 million in 2025.
- Its last three reported values are $739.4 million in Q3 2025, $827.9 million for Q2 2025, and $867.0 million during Q1 2025.